View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by Elsevier - Publisher Connector

Trials in Vaccinology 4 (2015) e75–e79

Contents lists available at ScienceDirect

Trials in Vaccinology

journal homepage: www.elsevier.com/locate/trivac

Analysis of recombinant, multivalent dengue virus containing envelope (E) proteins from serotypes-1, -3 and -4 and expressed in baculovirus

Fedik A. Rantam [a,b,*], Purwati [c], S. Soegijanto [a,d], H. Susilowati [a], K. Sudiana [e], E. Hendrianto [a], Soetjipto [f]

[a] *Dengue Hemorrhagic Fever Laboratory, Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia*
[b] *Virology and Immunology Lab, Microbiology Department, Vet. Medicine Faculty, Airlangga University, Surabaya, Indonesia*
[c] *Tropical and Infectious Diseases Division, Department of Internal Medicine, Dr. Soetomo Hospital/Teaching Hospital School of Medicine, Airlangga University, Surabaya, Indonesia*
[d] *Tropical and Infectious Diseases Division, Department of Pediatrics, Dr. Soetomo Hospital/Teaching Hospital School of Medicine, Airlangga University, Surabaya, Indonesia*
[e] *Pathology Department, School of Medicine, Airlangga University, Surabaya, Indonesia*
[f] *Biochemistry Department, School of Medicine, Airlangga University, Surabaya, Indonesia*

ARTICLE INFO

Article history:
Received 21 October 2013
Accepted 23 October 2013
Available online 5 December 2013

Keywords:
Dengue virus
Envelope gene
Recombinant E protein
Multivalent

ABSTRACT

Dengue virus has four serotypes that cause a public health problem in Indonesia. Currently, there is no preventative vaccine for this disease, but some model vaccines are in development. The envelop (E) protein genes from three isolates of dengue virus (DENV-1, -3 and -4) were isolated, cloned into *Escherichia coli* and then sub-cloned into a baculovirus vector before co-transfection into Sf9 cells. Recombinant E genes were inserted between the *Sma*I and *Sac*I sites of the plasmid, adjacent to the baculoviral structural gene, polyhedrin. The sequence of recombinant E gene was relatively stable with 97–98% homology, although there were amino acid substitutions in some regions. The recombinant protein was more antigenic when exposed to polyclonal sera from infected humans than sera from immunized mice, but its binding to monoclonal antibodies IgG1a and IgG2b was stronger than other isotopes, including IgM, IgG and Ig1b. Recombinant E protein induced cellular immune responses in immunized mice, as demonstrated by lymphocyte secretion of IL-3. This study indicates that recombinant E protein expressed in a baculovirus system can induce humoral and cellular immune responses.
© 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Introduction

Dengue virus is negative-sense, single-stranded RNA virus of the Flavivirus family; it has four serotypes that are endemic across Indonesia [12,15] and other tropical countries. The virus causes mostly pediatric morbidity and mortality [5]. The two types of dengue virus protein are structural and non-structural; their functions are genome replication (polymerase) and induction of antibodies. Structural proteins include the capsid (C), premembrane (prM), matrix (M) and envelop (E) proteins. E protein is important for attachment to cell membranes during infection, and it has many epitopes that react with neutralizing antibodies (Rey et al., 1995). Envelope protein is a glycoprotein, which has been studied for its antigenicity and immunogenicity [2,6] and especially explored an epitope type [10]. The severity of dengue virus disease was correlated with serotype. Serotypes 2 and 3 are more virulent than serotypes 1 and 4 [15], although antibody dependent enhancement has an effect [11]. Thus, vaccines would be effective in preventing dengue virus infections.

Potential dengue virus vaccines have been developed, but they may not protect against all serotypes. Recombinant protein vaccines with many epitopes have been produced for yellow fever virus and baculovirus (lobigs et al., 1987; [17], but it is not clear which antigen determines the induction of neutralizing antibodies. The baculovirus expression system has been used extensively for the expression of recombinant proteins [7] because it is a large, enveloped virus with double-stranded, circular DNA genome [4]. In this paper, we used a baculovirus system to express a multivalent, recombinant E protein for vaccine subunit development. The baculovirus insect cell expression system has been extensively developed. The most commonly used insect host cells include the Sf9 and sf21AE cell lines, originally derived from *Spodoptera frugiperda* pupal ovarian tissue [7]. In our studies, Sf9 cells were used.

* Corresponding author at: Institute of Tropical Disease, Dengue Hemorrhagic Fever Laboratory, Surabaya, Indonesia. Tel.: +62 (031) 5992445.
E-mail address: fedik.ar@gmail.com (F.A. Rantam).

http://dx.doi.org/10.1016/j.trivac.2013.10.001
1879-4378/© 2013 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Materials and methods

Virus and clinical specimens

The DENV-1, -3 and -4 strains were isolated from the sera of 62 human patients. Serum samples were collected by Dr. Soegijanto of the Child Health Department, Dr. Soetomo Teaching Hospital/School of Medicine, Airlangga University, from 2000 to 2008. Dengue virus isolates were selected by their biological properties, including cytopathic effect (CPE) and plaque-forming unit titers on infected Vero cells. Vero cells were kindly provided by Dr. Morita at Nagasaki University. DENV-1, -3 and -4 strains were isolated in 2008, 2004 and 2003, respectively, at the Dengue Hemorrhagic Fever laboratory, Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia, and were identified by multiplex RT-PCR as described by Lanciotti et al. [8].

RNA extraction, RT-PCR amplification, cloning and transfection

RNA was extracted from the supernatants of Vero cells infected with DEN-1, -3, or -4 and reverse transcribed to cDNA using random hexamer primers. cDNA was amplified using PCR conditions modified from Bielefeldt-Ohmann et al. [1] and Dos Santos et al. (2004). The following primers were used: forward Den1/Env/5′-G GGGGCTTCAACATCCCAAG-3′, reverse Den1/Env/5′-GTGCTCC ACG GGCAGTTGTC-3′, forward Den3/Env/5′-AGGGGCTACAAC AGAA AC AC-3′, reverse Den3/Env/5′-TTGCACCTCTGGCAGTGGCC-3′, forward Den4/Env/5′-AGGAGCAGACACATCAGAAG-3′, reverse Den4/Env/5′-TTGCACCTCTGTATGTGGAC-3′. PCR products were digested with the restriction endonuclease *EcoR1*, which cleaves at the joining site of the three E proteins, to minimize disruptions to protein secondary structure. The E protein genes were cloned individually into plasmid pGem and shuttle vectors (Promega) and subsequently ligated at the *EcoR1* sites. The sequences were subcloned into the baculovirus transfer vector pVL (Stratagene). For cloning and transfer into the baculovirus transfer vectors, *SmaI* and *Sac1* were used at the 5′ and 3′ ends, respectively, according to the modified method of Deuble et al. [3] and Kost and Condreay [7]. The recombinant virus was transfected according to the method of Bielefeldt-Ohmann et al. [1]. To ensure the molecular properties of recombinant E protein, the truncated protein E PCR product was sequenced using a method modified from Ong et al. [12], and amino acid analysis was performed using ClustalW Mega 5 software.

Production of recombinant E protein

Confluent Sf9 cell monolayers in 75-cm^2 tissue culture flasks were inoculated with the recombinant baculoviruses at an MOI of 1 in 3 ml medium. After 1 h, 7 ml serum-free medium was added. The conditioned medium was collected after 72 h, and the proteins were precipitated with 9% final concentration sterile polyethylene glycol 6000 (PEG, BDH) and overnight incubation with stirring at 4 °C. The precipitates were pelleted by centrifugation at 14,000*g* for 5 h and resuspended in sterile TNE buffer. The protein was used directly for analysis using a method modified from Bielefeldt-Ohmann et al. [1].

SDS–PAGE and western blotting

The recombinant dengue virus envelope proteins were separated using non-reducing 12% SDS–PAGE. The proteins were transferred onto nitrocellulose membranes by electroblotting in a methanol, glycine and Tris-buffer, and membranes were blocked with 1% bovine serum albumin (BSA) for 1 h [14]. The membranes were incubated with dengue virus-specific primary monoclonal antibody (mAb). After washing with Tris-buffered saline containing 0.1% Tween 20 and 1% BSA, primary polyclonal antibody was added. Following the washes, alkaline phosphatase-conjugated rabbit anti-mouse antibody (Dako) was added. Finally, nitrocellulose membranes were stained with Fast Red.

Immunotyping – ELISA

Microplates (96-well, Nunc) were coated with purified recombinant protein overnight at 4 °C, washed with PBS containing Tween 20 (PBST) and blocked for 1 h at room temperature with 1% BSA. After three washes with PBST, the primary mAb goat anti-mouse IgM, IgG, Ig1a, Ig1b and Ig2b (Dako) were diluted appropriately in PBS and incubated on the plates for 1 h at 37 °C. After three washes with PBST, horseradish peroxidase-conjugated anti-mouse immunoglobulin (Dako) was diluted in PBS and added to the wells. Following incubation for 45 min at 37 °C, the plates were washed three times with PBST, and ortho-phenylenediamine (OPD) substrate (Sigma) was added. The plates were incubated 10 min in the dark. After the addition of 1 M HCl, the plate was read on an ELISA reader (Bio-Rad) with the 450-nm wavelength. This method was modified from Bielefeldt-Ohmann et al. [1] and Rantam [14].

Immunization of mice and spot-ELISA

Three groups of 15 BALB/c mice (male, Veterinary Farma, Surabaya, Indonesia) were immunized by the intraperitoneal route with 15 μg of purified recombinant E protein mixed with Montaned 70 adjuvant (Seppic, Institute Pasteur). All mice were sacrificed at 14 days post-immunization, and spleen cells were isolated as described by Bielefeldt-Ohmann et al. [1] to analyze the secreted cellular immune response by ELISpot as described by Mabtech. All animal experiments were conducted with institutional ethics approval in accordance with the Faculty of Veterinary Medicine, Airlangga University, Surabaya, Indonesia.

Results

Virus culture and identification

Dengue viruses caused cytopathogenic effect (CPE) in 60–80% of Vero cells after passage 3–4, indicating that the virus was growing in these cells. Viruses were harvested, and RNA was extracted for serotype identification. The virus titers were determined by indirect ELISA (data not shown). While all dengue virus serotypes induced CPE in cell culture, DENV-4 replicated less rapidly than DENV-1 and DENV-3, as shown in Fig. 1. RT-PCR was used to identify dengue virus isolate serotypes.

In Fig. 2b, cDNA was amplified from the selected serotypes. The E protein genes of DENV-1, -3 and -4 were cloned individually and subsequently fused in a single plasmid, as illustrated in Fig. 3. To construct the recombinant envelope protein gene, a DNA fragment of 1744 nucleotides was cloned. The dengue virus E protein gene in this construct was placed under the transcriptional control of the baculovirus polyhedrin promoter. Additionally, the dengue virus RNA transcripts contained an authentic initiation codon and produced recombinant E proteins (Fig. 3). The recombinant DNA and baculovirus genomic DNA were co-transfected into Sf9 cells, resulting in homologous recombination, as indicated by western blotting and plaques in Sf9 cells (Fig. 4a, b and Fig. 5a).



Fig. 1. Dengue virus-infected Vero cells. (N) Normal Vero cell. (A) Vero cells infected with DENV-4 at six days after inoculation. (B) Vero cells infected with DENV-1. (C) Vero cells infected with DENV-3. The CPE observed for DENV-1 and DENV-3 were relatively similar, although the virus virulence in vitro was very different. Arrows indicate cytopathic effect.



Fig. 2. (A) Identification of dengue virus serotypes in supernatants of infected Vero cells using multiplex RT-PCR. Lane D1: DENV-1, Lane D3: DENV-3, Lane D4: DENV-4, Lane N: negative control and Lane M: marker. (B) PCR was used to amplify the dengue envelope genes of DENV-1, -3 and -4 (ED-1, -3 and -4) from infected Vero cells. Serotype-specific primers resulted in PCR products of approximately 582 bp. Lane p; the positive control DENV-2.



Fig. 3. Construction of recombinant envelope (E) protein. DENV-1, -3 and -4 E genes were inserted into the baculovirus system using an intermediate vector. Vector pVL contains the polyhedrin structural gene. A fragment of the viral structural protein open reading frame (nucleotides 892–2092) was ligated into the *SmaI* site of pVL. The recombinant cDNA fragment containing the insert in the sense orientation was isolated for the construction of recombinant baculovirus, which was transfected into AcNPV cells. Sf9 cells were infected with the resulting baculovirus.

Stability of recombinant E proteins gene

Recombinant envelope protein genes from DENV-1, -3 and -4 (ED1, ED3, ED4) were cloned into a baculovirus vector, which was transfected into Sf9 cells. Some virus plaques were formed in these cells (Fig. 4a). DNA purified from plaques in Sf9 cell cultures was used to evaluate the stability of recombinant E protein genes. The results from alignment analyses in the *ClustalW* MEGA5 software are shown in Fig. 4b and Table 1. Nucleotides were 97–98% homologous and stable, although there were some amino acid substitutions (Table 2).

Amino acid substitutions are shown in Table 2. There were no dominant changes, but in the region of recombinant E protein ED1, there were only serine (S) and cysteine (C) to arginine changes with E value scores of 2e-132.

Recombinant dengue virus E proteins have some nucleotide changes. Some regions of ED1 and ED3 have the highest and lowest scores, respectively, with 97–98% similarity to the original sequence and 5,3% variable sites (Table 1).

There were no amino acid variants except serine (S) to arginine (R), cysteine (C) to arginine, lysine (K) to glutamate (E), histidine (H) to tyrosine (Y), phenylalanine (F) to leucine (L), valine (V) to alanine (A) and glutamate to asparagine (N) changes (Table 2).

Antigenicity and reactivity of recombinant E protein

Recombinant E proteins were purified from baculovirus-infected Sf9 cells, digested with a naphthol 40 solution, separated by SDS–PAGE and transferred onto nitrocellulose membranes using an electroblotter (Goettingen) (Fig. 5a, b).

Purified recombinant E proteins were isolated using Talon (Invitrogen) and mixed with the adjuvant surfactant monteneid-SEPPIC (Institute Pasteur, France); each mouse was immunized with 15 μg of the mixture. The reaction of recombinant E protein with monoclonal antibody (mAb) was analyzed using indirect ELISA (Fig. 6). Recombinant E protein showed the highest reactivity to IgG1a and IgG2b.

ELISpot assays were used to analyze the immunogenic function of recombinant E protein (Fig. 7a). Interleukin-3 in immunized mice (group 1) was relatively high, and spot counts were similar in a replicate experiment (group 2). These results indicate that recombinant E proteins induced a robust cellular immune response.



Fig. 4. RT-PCR assay of recombinant E protein using a β-actin control. (A) Agrophaga cells infected with recombinant baculovirus. The arrowhead indicates an infected cell. (B) M: marker, Lane 1: cells infected with baculovirus, Lane 2: non-infected cells, Lanes 3–5: cells infected with recombinant baculovirus.



Fig. 5. Antigenic reactivity of recombinant E proteins. (A) Western blotting: Recombinant E proteins were separated by 12% SDS–PAGE, transferred onto nitrocellulose membranes and incubated with dengue virus-specific antibody after blocking with 1% BSA. Lane M: protein marker, Lane 1: recombinant E protein was reacted with MAb IgG1a. Lanes 2, 5, 6: Visualization of recombinant E protein reacted with sera from DHF patients, which was collected by ITD from Dr. Soetomo Teaching Hospital-UA. Lane 4: recombinant E protein was reacted with MAb IgG2b. N: recombinant E protein was reacted with normal human sera and stained with Fast Red. (B) Western blot analysis showed weak reactivity. Lane 1: Recombinant E protein was incubated with mAb IgG1a. Lanes 2–6: Recombinant E protein was reacted with sera from immunized mice. Lane N: normal sera from unimmunized mice. Arrowheads indicate a molecular mass of 52 kDa, and the molecular mass markers at 32 and 49 kDa are indicated. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Table 1
Nucleotide homology between recombinant E genes and the original DENV-1, -3, and -4 E gene sequences.

Description	Max score	Total score	Query cover	E Value	Identity
ED1	359	359	98%	2e-132	98%
ED3	354	354	100%	3e-130	97%
ED4	355	355	99%	7e-131	98%

Table 2
Amino acid substitutions in the recombinant E protein regions ED-1, -3, and -4.

Comparing	Amino acid changing						
Original sequence	S	C	K	H	F	V	E
Recombinant sequence ED1	R	R					
Recombinant sequence ED3			E	Y	L		
Recombinant sequence ED4						A	N



Fig. 6. Analysis of recombinant E protein antigenicity. Indirect ELISA was used to confirm that recombinant E protein induced an immune response. Recombinant E proteins were reacted with various isotypes of mAb (IgM, IgG, IgG1a, IgG2a, IgG2b).

IL-3 secreted from lymphocytes was clearly visualized, and every cell had a different production of IL-3 (Fig. 7b).

Discussion

Dengue viruses have different levels of virulence. These viruses were isolated via blind passaging or 3–4 subcultures in Vero cells. Replicating virus was identified by the induction of cytopathic effect (CPE) (Fig. 1), although not all serotypes caused CPE in cell cultures. To identify virus serotypes, multiplex RT-PCR was used as in Lanciotti et al. [8], and different products were observed in each serotype (Fig. 2a). The expression of dengue viral recombinant E protein of virus infected cells contained antigen have showed some plaque forming unit in Sf9 as in Fig. 4a. This result indicates that viral proteins were expressed from baculovirus vectors, regenerating viruses in Sf9 cells.

Protein expression was analyzed by western blotting. Proteins were separated by SDS–PAGE, transferred to nitrocellulose membranes and strafed 3 mm. The results show that the reactivity of recombinant E protein with monoclonal IgG1a and IgG1a antibody is relatively weak compared with the reactivity of sera from DHF patients. Thus, the protein recognized more polyclonal than mAbs, although the reactivity of protein and antibody was significantly different (Fig. 5a) because the immune response to dengue virus protein depends on the individual infected dengue virus [13]. However, polyclonal antibodies from the sera of humans infected with dengue virus can possibly react to many types of non-specific dengue virus epitopes. The antigenicity of recombinant E protein in polyvalent immunized mice sera was weaker than in sera from humans infected with dengue virus (Fig. 5b). Because the immunization of mice consisted of a single dose, it is possible that antigenicity would be higher with 2–3 booster immunizations [1]. In this case, recombinant E protein induced strong responses in BALB/c mice.

To analyze cellular response immunes, lymphocytes from immunized mice were cultured in vitro with recombinant E protein. ELISpot analysis showed that IL-3 was secreted in vitro by all lymphocytes. In this case, the original secretion of IL-3 was very difficult to prove, and currently no other data supports this finding. Secreted IL-3 was not detected in normal lymphocytes from the



Fig. 7. Mice lymphocytes secreting IL-3 were analyzed by ELISpot after four days of in vitro culture. (A) IL-3 spots; *n* = 5 mice. Control: immunized using the adjuvant Seppic, group 1: lymphocytes from mice immunized with recombinant E proteins, group 2: lymphocytes from mice immunized with inactive dengue virus (DENV-1, -3 and -4) at 10^7 $TCID_{50}$. (B) Representative ELISpot of IL-3 secreted from mice immunized mice with recombinant E protein. The white arrowhead indicates IL-3 spots.

control group. The results from groups 1 and 2 were similar and significantly different from the control group. The level of secreted IL-3 may be correlated with the recognition of an epitope of the recombinant protein. This event occurs before stimulated macrophages release IFN-γ, which initiates signaling in the cellular immune response [9,1].

Lymphocyte susceptibility depends on age, strain, animal and route of immunization [16]. The type of adjuvant and recombinant E protein structure, but not amino acid changes, may contribute less to immunogenicity. In contrast, changing the amino acids serine, alanine, histidine and asparagine in recombinant E proteins could lead to the induction of a stronger immune response or enhanced antibodies. In these cases, amino acid changes can influence the recombinant E protein structure. Because this system produces relatively stable recombinant E protein, immunogenic proteins can be developed via this method for use in multivalent vaccines or diagnostic tests.

Acknowledgements

We thank Dr. Morita of the Virology Department, Institute of Tropical Medicine, Nagasaki University, Japan, for the kind gift of C6/36 cells and Dr. Yamanaka at CRC-ERID, Kobe University, Japan, for providing Vero cells. This work was supported by grants from the SINAs Research Program, Ministry of Research and Technology, Indonesia Republic, Health and Drug Technology. We thank all technicians for their technical assistance at DHF Laboratory, Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia.

References

[1] H. Bielefeldt-Ohmann, D.W.C. Beasly, D.R.F. Fitzpatrick, G. Asskov, Analysis of recombinant dengue-2 virus, dengue-3 virus hybrid envelope protein expresseed in a secretory baculovirus system, J. Gen. Virol. 78 (1997) 2723–2733.

[2] C. Delenda, I. Staropoli, M.P. Frenkiel, L. Cabanie, V. Deuble, Analysis of C terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins, processing in insect cells and immunogenic properties in mice, J. Gen. Virol. 75 (1994) 1569–1576.

[3] V. Deuble, R.M. Nogueria, F. Megret, M.K. Gentry, J.J. Schlesinger, M. Girad, Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed insect cells by recombinant baculovirus, Virology 180 (1991) 442–447.

[4] R. Grabherr, W. Ernst, C. Oker-Blom, I. Jones, Developments in the use of baculovirus for the surface display of complex eukaryotic proteins, Trends Biotechnol. 19 (2001) 231–236.

[5] D.J. Gubler, Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century, Trends Microb. 10 (2002) 100–103.

[6] Z. Jianmin, M.L. Linn, R. Billch, M.K. Gentry, J.G. Aaskov, Analysis of functional epitopes on the dengue 2 E protein using monoclonal igM antibodies, Arch Virol. 140 (1995) 899–913.

[7] T.A. Kost, J.P. Condreay, Recombinant baculovirus as mammalian cell gene-delivery vectors, Trends Biotechnol. 20 (2002) 173–180.

[8] R.S. Lanciotti, C.H. Calisher, D.J. Gubler, G.J. Chang, A.V. Vondam, Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction, J. Clin. Microbiol. 30 (1992) 545–551.

[9] E. Maraskovsky, A.B. Troutt, A. Kelso, Co-engagement of CD-3 with LFA-1 or ICAM-1 adhesion molecules enhances the frequency activation of single murine CD4+ and CD8+ T cells and induces synthesis of IL-3 and IFN-γ but not IL-4 or IL-6, Int. Immunol. 4 (1992) 475–485.

[10] F. Megret, J.P. Hugnoy, A. Falconer, M.K. Gentry, D.M. Morens, J.M. Murray, J.J. Schlesinger, P.J. Wright, P. Young, H.V. Van Regenmortel, V. Deuble, Proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein, Virology 187 (1992) 480–491.

[11] D.M. Morens, Antibody-dependent enhancement of infection and the pathogenesis of viral disease, Clin. Infect. Dis. 19 (1994) 500–512.

[12] J.T. Ong, J.T. Yip, Y.L. Chen, W. Liu, S. Harun, E. Lystiyaningsih, B. Heriyanto, C.G. Beckett, W.P. Mitchell, M.L. Hibberd, A. Suwandono, S.G. Vasundevan, M.J. Schreiber, Periodeic re-emergence of endemic strains with strong epidemic potential. A proposed explanation for the 2004 Indonesian dengue epidemic infection, Genet. Evol. 8 (2008) 191–204.

[13] F.A. Rantam, Soegijanto, S. Soetjipto, Y.P. Dahlan, K. Sudiana, Establish model of recombinant E protein dengue virus with baculovirus as clone subunit, Vaccine (2002) 57–63.

[14] F.A. Rantam, Immunology Methods, Airlangga University Press (2003) 89–94.

[15] F.A. Rantam, Purwati, A. Tedjo, D. Lee, E. Hendrianto, H. Susilowati, D. Kartika, P. Anas, Y. Benediktus, S. Soegijanto, Nasronudin, Serotype infectivity and phylogenetic of dengue virus cause of dengue fer (DF), dengue hemorrhagic fever (DHF), and Dengue shock syndrome (DSS) in Surabaya-Indonesia, AJIM Int. Scholarsh. J (1) (2013) 031–036.

[16] M. Sarzotti, D.D. Robbins, P.M. Hoffman, Induction of protective CTL response in newborn mice by murine retrovirus, Science 271 (1996) 1726–1728.

[17] I. Satropoli, J.M. Clement, M.P. Frenkiel, M. Hofnung, V. Deuble, Dengue virus envelope glycoprotein can be secreted from insect cells as fusion with the maltose-binding protein, J. Virol. Method 56 (1996) 179–189.